These findings highlight key molecular distinctions in PC, particularly the lower prevalence of TGF-Beta pathway alterations in H/L patients, which may have implications for disease progression, tumor microenvironment interactions, and therapeutic response. The gene discussed is TGFB1; the disease is pachyonychia congenita.